Effects of liraglutide combined with metformin and Diamicron on glucose-lipid metabolism and islet β-cell function in elderly patients with type 2 diabetes mellitus

We explored the therapeutic effects of liraglutide combined with metformin and Diamicron in elderly patients with type 2 diabetes mellitus (T2DM) and the effects of this regimen on glucose - lipid metabolism and islet beta-cell function. Ninety-two elderly patients with T2DM admitted to our hospital were selected as research participants. Of these, 42 patients treated with metformin and Diamicron were included in the control group (CG) and the remaining 50 patients treated with liraglutide combined with metformin and Diamicron were enrolled in the research group (RG). The total rate of efficacy in RG was significantly higher than that in CG (P < 0.05); however, there was no significant difference in the incidence of adverse reactions (P > 0.05). Moreover, no marked differences were observed in glucose-lipid metabolism indexes and islet beta-cell function between the two groups before treatment (P > 0.05). After treatment, fasting plasma glucose, 2-h postprandial blood glucose, and glycosylated hemoglobin levels remarkably decreased in both groups, and these levels were significantly lower in RG than in CG (P < 0.001). Liraglutide combined with metformin and Diamicron can effectively improve glucose - lipid metabolism in elderly patients with T2DM and enhance islet beta-cell function with improved clinical efficacy.